Abstract
Over 40% of cancer patients will require radiation therapy during management of their disease. Although radiation therapy improves the survival of a significant number of cancer patients, both acute radiation toxicity (which manifests during a course of clinical radiotherapy or shortly thereafter), and late toxicity (developing months to years after completion of radiotherapy) compromise overall outcomes for successfully treated cancer patients.
- Received November 24, 2008.
- Revision received January 9, 2009.
- Accepted January 26, 2009.
- Copyright © 2009 The Author(s). Published by the International Institute of Anticancer Research.
In this issue
Jump to section
Related Articles
Cited By...
- Second-generation Probiotics Producing IL-22 Increase Survival of Mice After Total Body Irradiation
- Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation
- Antibiotic-induced shifts in fecal microbiota density and composition during hematopoietic stem cell transplantation
- Unique epigenetic influence of H2AX phosphorylation and H3K56 acetylation on normal stem cell radioresponses
- Silencing Egr1 Attenuates Radiation-Induced Apoptosis in Normal Tissues while Killing Cancer Cells and Delaying Tumor Growth
- A Mobile Alert System for Preparing the Delivery of Radiation Mitigators
- New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology
- The Zebrafish- Danio rerio - Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation
- Bactericidal/Permeability-Increasing Protein (rBPI21) and Fluoroquinolone Mitigate Radiation-Induced Bone Marrow Aplasia and Death
- Uncoupling p53 Functions in Radiation-Induced Intestinal Damage via PUMA and p21
- Screening of Antimicrobial Agents for In Vitro Radiation Protection and Mitigation Capacity, Including those Used in Supportive Care Regimens for Bone Marrow Transplant Recipients
- High-Throughput Screening Identifies Two Classes of Antibiotics as Radioprotectors: Tetracyclines and Fluoroquinolones
- Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling